Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:26
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [21] Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations
    Villiger, Angela
    Stillhart, Cordula
    Parrott, Neil
    Kuentz, Martin
    AAPS JOURNAL, 2016, 18 (04): : 933 - 947
  • [22] Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations
    Angela Villiger
    Cordula Stillhart
    Neil Parrott
    Martin Kuentz
    The AAPS Journal, 2016, 18 : 933 - 947
  • [23] Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel
    Zhu, Jinying
    Zhao, Yuqing
    Wang, Lu
    Zhou, Chen
    Zhou, Sufeng
    Chen, Tao
    Chen, Juan
    Zhang, Zeru
    Zhu, Ying
    Ding, Sijia
    Shao, Feng
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 167
  • [24] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING FOR PREDICTING TRANSPORTER-MEDIATED DRUG DISPOSITION IN HUMANS
    Watanabe, Takao
    Kusuhara, Hiroyuki
    Maeda, Kazuya
    Shitara, Yoshihisa
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2007, 39 : 98 - 98
  • [25] Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development
    Shardlow, Carole E.
    Generaux, Grant T.
    Patel, Aarti H.
    Tai, Guoying
    Thuy Tran
    Bloomer, Jackie C.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (12) : 1994 - 2003
  • [26] Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
    Ji, Beihong
    Liu, Shuhan
    Xue, Ying
    He, Xibing
    Viet Hoang Man
    Xie, Xiang-Qun
    Wang, Junmei
    DRUGS IN R&D, 2019, 19 (03) : 297 - 305
  • [27] Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development: A Pharmaceutical Industry Perspective
    Jones, H. M.
    Chen, Y.
    Gibson, C.
    Heimbach, T.
    Parrott, N.
    Peters, S. A.
    Snoeys, J.
    Upreti, V. V.
    Zheng, M.
    Hall, S. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (03) : 247 - 262
  • [28] Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool
    Cheng, Lisa
    Wong, Harvey
    PHARMACEUTICS, 2020, 12 (07) : 1 - 18
  • [29] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
    Duan, P.
    Zhao, P.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S16 - S17
  • [30] Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
    Nakayama, Shintaro
    Lukacova, Viera
    Tanabe, Shuichi
    Watanabe, Akiko
    Mullin, Jim
    Suarez-Sharp, Sandra
    Shimizu, Takako
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (04): : 440 - 448